Cancer Urology

Онкоурология

1726-97761996-1812

Publishing House ABV Press

1123

10.17650/1726-9776-2007-3-3-57-62

DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCER

ДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак предстательной железы

Hormonal therapy for prostate cancer

Гормональная терапия больных раком предстательной железы

Alekseyev

B. Ya.

Алексеев

Б. Я.

Russian Federation

Nyushko

K. M.

Нюшко

К. М.

Russian Federation

Московский научно-исследовательский онкологический институт им. П.А. Герцена

30092007

57621602202016022020

https://oncourology.abvpress.ru/oncur/article/view/1123

1. Чиссов В.И., Старинский В.В. Онкологическая заболеваемость в России в 2005 году. М.; 2007.

Чиссов В.И., Старинский В.В. Онкологическая заболеваемость в России в 2005 году. М.; 2007.

2. Catalona W.J., Richie J.P., Ahmann F.R. et al. Comparison of digital rectal examination an serum PSA in the early detection of prostate cancer. J Urol 1994;151(5):1283—90.

Catalona W.J., Richie J.P., Ahmann F.R. et al. Comparison of digital rectal examination an serum PSA in the early detection of prostate cancer. J Urol 1994;151(5):1283—90.

3. Catalona W.J., Smith D.S., Ratliff T.L., Basler I.W. Detection of organ-confined prostate cancer is increased through PSA-based screening. JAMA 1993;150(3):1018—23.

Catalona W.J., Smith D.S., Ratliff T.L., Basler I.W. Detection of organ-confined prostate cancer is increased through PSA-based screening. JAMA 1993;150(3):1018—23.

4. Catalona W.J., Smith D.S., Ratliff T.L. et al. Measurment of PSA in serum as screening test for prostate cancer. N Engl J Med 1991;324(17):1156—61.

Catalona W.J., Smith D.S., Ratliff T.L. et al. Measurment of PSA in serum as screening test for prostate cancer. N Engl J Med 1991;324(17):1156—61.

5. Huggins C., Hoges C.V. Studies on prostate cancer: I. The effect of castration, of estrogen and of androgen injection of serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002;168(1):9—12.

Huggins C., Hoges C.V. Studies on prostate cancer: I. The effect of castration, of estrogen and of androgen injection of serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002;168(1):9—12.

6. Bayar D.P. Studies on prostate cancer and its treatment. 1977.

Bayar D.P. Studies on prostate cancer and its treatment. 1977.

7. Daneshgari F., Crawford E.D., Endocrine therapy of advanced prostate cancer. Cancer 1993;71(3 Suppl):1089—97.

Daneshgari F., Crawford E.D., Endocrine therapy of advanced prostate cancer. Cancer 1993;71(3 Suppl):1089—97.

8. Kaisary A.V., Tyrrell C.J., Peeling W.B., Griffiths K. Comparison of LHRH analogue with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991;67(5):502—8.

Kaisary A.V., Tyrrell C.J., Peeling W.B., Griffiths K. Comparison of LHRH analogue with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991;67(5):502—8.

9. Bolla M., Collette L., Blank L. et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360(9327):103—6.

Bolla M., Collette L., Blank L. et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360(9327):103—6.

10.

10. Lawton C.A., Winter K., Murray K. et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;49(4):937—46.

Lawton C.A., Winter K., Murray K. et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;49(4):937—46.

11.

11. Messing E.M. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003;170(5):1955; author reply 1955—6.

Messing E.M. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003;170(5):1955; author reply 1955—6.

12.

12. Quesnel M. Study on the administration of goserelin. Methodology and results. Soins 2007;(713):28—9.

Quesnel M. Study on the administration of goserelin. Methodology and results. Soins 2007;(713):28—9.

13.

13. Di Silverio F., Serio M. Zoladex in prostatic carcinoma. Drugs Exp Clin Res 1990;16 (Suppl):19—29.

Di Silverio F., Serio M. Zoladex in prostatic carcinoma. Drugs Exp Clin Res 1990;16 (Suppl):19—29.

14.

14. Klarskov P., Lund F., Petersen S.E. Secondary treatment of advanced cancer of the prostate with Zoladex. Int Urol Nephrol 1990;22(4):359—62.

Klarskov P., Lund F., Petersen S.E. Secondary treatment of advanced cancer of the prostate with Zoladex. Int Urol Nephrol 1990;22(4):359—62.

15.

15. Di Silverio F., Serio M., D'Eramo G., Sciarra F. Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study. Eur Urol 1990;18 (Suppl 3):54—61.

Di Silverio F., Serio M., D'Eramo G., Sciarra F. Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study. Eur Urol 1990;18 (Suppl 3):54—61.

16.

16. Boccardo F., Decensi A., Guarneri D. et al. Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an ongoing PONCAP study. Italian Prostatic Cancer Project (PONCAP). Eur Urol 1990;18 (Suppl 3):48—53.

Boccardo F., Decensi A., Guarneri D. et al. Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an ongoing PONCAP study. Italian Prostatic Cancer Project (PONCAP). Eur Urol 1990;18 (Suppl 3):48—53.

17.

17. Fourcade R.O., Cariou G., Coloby P. et al. Total androgen blockade with Zoladex plus flutamide vs. Zoladex alone in advanced prostatic carcinoma: interim report of a multicenter, double-blind, placebo-controlled study. Eur Urol 1990;18 (Suppl 3):45—7.

Fourcade R.O., Cariou G., Coloby P. et al. Total androgen blockade with Zoladex plus flutamide vs. Zoladex alone in advanced prostatic carcinoma: interim report of a multicenter, double-blind, placebo-controlled study. Eur Urol 1990;18 (Suppl 3):45—7.

18.

18. Iversen P. Zoladex plus flutamide vs. orchidectomy for advanced prostatic cancer. Danish Prostatic Cancer Group (DAPROCA). Eur Urol 1990;18 (Suppl 3):41—4.

Iversen P. Zoladex plus flutamide vs. orchidectomy for advanced prostatic cancer. Danish Prostatic Cancer Group (DAPROCA). Eur Urol 1990;18 (Suppl 3):41—4.

19.

19. Denis L., Smith P.H., De Moura J.L. et al. Orchidectomy vs. Zoladex plus flutamide in patients with metastatic prostate cancer. The EORTC GU Group. Eur Urol 1990;18 (Suppl 3):34—40.

Denis L., Smith P.H., De Moura J.L. et al. Orchidectomy vs. Zoladex plus flutamide in patients with metastatic prostate cancer. The EORTC GU Group. Eur Urol 1990;18 (Suppl 3):34—40.

20.

20. Moffat L.E. Comparison of Zoladex, diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer. Eur Urol 1990;18 (Suppl 3):26—7.

Moffat L.E. Comparison of Zoladex, diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer. Eur Urol 1990;18 (Suppl 3):26—7.

21.

21. Messing E.M., Manola J., Yao J. et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7(6):472—9.

Messing E.M., Manola J., Yao J. et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7(6):472—9.

22.

22. Pilepich M.V., Winter K., Lawton C.A. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61(5):1285—90.

Pilepich M.V., Winter K., Lawton C.A. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61(5):1285—90.

23.

23. Lawton C.A., Winter K., Grignon D., Pilepich M.V. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol 2005;23(4):800—7.

Lawton C.A., Winter K., Grignon D., Pilepich M.V. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol 2005;23(4):800—7.

24.

24. Hanks G.E., Pajak T.F., Porter A. et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003;21(21):3972—8.

Hanks G.E., Pajak T.F., Porter A. et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003;21(21):3972—8.

25.

25. Zinner N.R., Bidair M., Centeno A., Tomera K. Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial. Urology 2004;64(6):1177—81.

Zinner N.R., Bidair M., Centeno A., Tomera K. Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial. Urology 2004;64(6):1177—81.

26.

26. Fontana D., Mari M., Martinelli A. et al. 3-month formulation of goserelin acetate ('Zoladex' 10.8-mg depot) in advanced prostate cancer: results from an Italian, open, multicenter trial. Urol Int 2003;70(4):316—20.

Fontana D., Mari M., Martinelli A. et al. 3-month formulation of goserelin acetate ('Zoladex' 10.8-mg depot) in advanced prostate cancer: results from an Italian, open, multicenter trial. Urol Int 2003;70(4):316—20.

27.

27. Tsukagoshi S. A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10.8 mg depot)-out-line of pre-clinical and clinical studies. Gan To Kagaku Ryoho 2002;29(9): 1675—87.

Tsukagoshi S. A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10.8 mg depot)-out-line of pre-clinical and clinical studies. Gan To Kagaku Ryoho 2002;29(9): 1675—87.

28.

28. Trueman J.A., Tillmann V., Cusick C.F. et al. Suppression of puberty with long-acting goserelin (Zoladex-LA): effect on gonadotrophin response to GnRH in the first treatment cycle. Clin Endocrinol (Oxf) 2002;57(2):223—30.

Trueman J.A., Tillmann V., Cusick C.F. et al. Suppression of puberty with long-acting goserelin (Zoladex-LA): effect on gonadotrophin response to GnRH in the first treatment cycle. Clin Endocrinol (Oxf) 2002;57(2):223—30.

29.

29. Kotake T., Akaza H., Usami M. et al. Clinical effects of a 3-month formulation LH-RH agonist (Zoladex LA 10.8 mg depot) in patients with prostate cancer. Hinyokika Kiyo 2001;47(5):349—61.

Kotake T., Akaza H., Usami M. et al. Clinical effects of a 3-month formulation LH-RH agonist (Zoladex LA 10.8 mg depot) in patients with prostate cancer. Hinyokika Kiyo 2001;47(5):349—61.

30.

30. Sarosdy M.F., Schellhammer P.F., Soloway M.S. et al. Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. BJU Int 1999;83(7):801—6.

Sarosdy M.F., Schellhammer P.F., Soloway M.S. et al. Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. BJU Int 1999;83(7):801—6.

31.

31. Fernandez del Moral P., Dijkman G.A., Debruyne F.M. et al. Three-month depot of goserelin acetate: clinical efficacy and endocrine profile. Dutch South East Cooperative Urological Group. Urology 1996;48(6):894—900.

Fernandez del Moral P., Dijkman G.A., Debruyne F.M. et al. Three-month depot of goserelin acetate: clinical efficacy and endocrine profile. Dutch South East Cooperative Urological Group. Urology 1996;48(6):894—900.